{"organizations": [], "uuid": "468412ca7a54eaf02611b1f4669b84666fa9a5f3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/02/pr-newswire-yew-bio-pharm-group-reports-2017-fourth-quarter-and-full-year-financial-results.html", "country": "US", "domain_rank": 767, "title": "Yew Bio-Pharm Group Reports 2017 Fourth Quarter and Full Year Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-03T00:10:00.000+03:00", "replies_count": 0, "uuid": "468412ca7a54eaf02611b1f4669b84666fa9a5f3"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/02/pr-newswire-yew-bio-pharm-group-reports-2017-fourth-quarter-and-full-year-financial-results.html", "ord_in_thread": 0, "title": "Yew Bio-Pharm Group Reports 2017 Fourth Quarter and Full Year Financial Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "calif.", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "yew bio-pharm group, inc.", "sentiment": "neutral"}, {"name": "tcm", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "EL MONTE, Calif., April 2, 2018 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. (\"Yew Bio\" or the \"Company\") (OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine, handicraft products made from yew timber and yew candle and soap made with yew essential oil in China, today reported financial results for the three- and twelve-months ended December 31, 2017.\n2017 Fourth Quarter Results\nThree Months Ended December 31,\nTwelve Months Ended December 31,\n2017\n2016\n2017\n2016\nRevenues:\nTCM Raw Materials\n$3,169,400\n$4,703,017\n$20,180,406\n$28,766,815\nYew Trees\n72\n(387)\n9,978\n22,859\nHandicrafts\n45,275\n643\n50,559\n98,203\nOthers\n2,280,188\n7,297,231\n20,298,747\n22,460,205\nTotal Revenues\n$5,494,935\n$12,000,504\n$40,539,690\n$51,348,082\nTotal revenue for the fourth quarter of 2017 decreased 54.2% to $5.5 million from $12.0 million a year ago. Sales of TCM raw materials amounted to 57.7% of total revenues; sales of others segment consisting with yew essential oil candle, yew essential oil soap, pine needle extract, complex Taxus Cuspidate extract and composite northeast yew extract amounted to 41.5% of total revenues; sales of handicrafts amounted to 0.8% of total revenues, and sales of yew trees amounted to 0.0% of total revenues which is due to the Company's strategy adjustment to reserve more yew trees for future TCM raw materials sales.\nFor the 2017 fourth quarter, gross profit was a loss of $6.8 million, compared with a loss of 1.2 million. The loss for the fourth quarter of 2017 was primarily due to adjustment of inventory and yew forest assets based on our physical inventory observation.\nOperating expenses increased 460.9% to $878,089 for the 2017 fourth quarter, from $156,546 in the year-ago quarter. The increasing was primarily attributable to the increase in compensation and related benefits and Other fees.\nNet income in the fourth quarter of 2016 was a loss of $7.8 million, or a loss of $0.14 per diluted share, compared with a loss of $1.4 million in the year-ago quarter, or a loss of $0.03 per diluted share.\n2017 Results\nTotal revenues for the 2017 fiscal year were $40.5 million, a 21.0% decrease from $51.3 million a year earlier. Sales of TCM raw materials amounted to 49.8% of total revenues, sales of yew trees amounted to 0.0% of total revenues, sales of handicrafts amounted to 0.1% of total revenues and sales of others consisting with yew essential oil candle, yew essential oil soap, pine needle extract, complex Taxus Cuspidate extract and composite northeast yew extract made up the remaining 50.1%.\nGross profit was $5.1 million, or 12.5% of total revenues, for the full year, compared with $3.2 million, or 6.3% of total revenues in 2016.\nOperating expenses increased 56.1% to $1.7 million for the 2017, from 1.1 million a year earlier. The increasing was primarily attributable to the increases in compensation and related benefits and Other fees.\nNet income for 2017 increased to $3.2 million, or 0.06 per diluted share, from $2.0 million, or $0.04 per diluted share for 2016.\n\"Our TCM raw materials and Others segment sales contributed most of our revenues for the year 2017,\" said Mr. Zhguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group, Inc. \"We developed a series of yew product derivatives such as yew oil candle, yew essential oil soap, face serum and moisturizer cosmetics which contain yew essential oil, functional pillow, complex Taxus Cuspidate extract and composite northeast yew extract since from year 2015, and these products have been accepted by more and more customers of the U.S. and Chinese market. We also established a yew product retail and experience store in San Gabriel, California in 2017, and we hope to introduce our yew products to the U.S. customers by establishing more experience stores in the future.\"\n\"Our face serum and moisturizer cream cosmetics containing yew essential oil had formally launched to the market during the fourth quarter of 2017, and now we are working with our Chinese distributors to complete the application to export to Chinese market. We expect the application to be finished during six to nine months. Meanwhile, we are also exploring major U.S. distributors to seek listing our cosmetics on the shelf. As we announced in the earlier news, we have been through to explore the transformation of the Company's business model from a forestry company to a high value-added manufacturer mainly utilizes the yew tree raw materials as basis. Looking ahead in 2018, we will continue to enrich our product mix and develop more value-added products for the Company, and we expect the Company to achieve sustained growth with the new business.\"\nABOUT YEW BIO-PHARM GROUP, INC\nYew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. Yew Bio-Pharm also recently established a division to focus on organic foods and dietary supplements with the aim of developing new business opportunities in related industries. To learn more, please visit www.yewbiopharm.com\nSAFE HARBOR\nThis press release forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements involve a number of risks and uncertainties that could cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: our ability to collect from our largest customers; our dependence on a small number of customers for raw materials, including a related party; our ability to continue to purchase raw materials at relatively stable prices; our dependence on a small number of customers for our yew trees for reforestation; our ability to market successfully raw materials used in the manufacture of traditional Chinese medicines; and our ability to receive continued preferential tax treatment for the sale of yew trees and potted yew trees. From time to time, these risks, uncertainties and other factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K. Yew Bio does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise, except as required under applicable law.\nCompany Contact:\nHenry Pang\nYew Bio-Pharm Group, Inc.\nTel: (626) 401-9588\nhpang@yewbiopharm.com\n(financial tables follow)\nYEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES\nCONSOLIDATED BALANCE SHEETS\nDecember 31,\n2017\n2016\nASSETS\nCURRENT ASSETS:\nCash\n$\n859,830\n$\n278,991\nAccounts receivable\n9,881,914\n14,467,852\nAccounts receivable - related parties\n21,847,733\n6,941,931\nInventories, net\n2,579,190\n10,296,792\nPrepaid expenses - related parties\n57,202\n76,995\nPrepaid expenses and other assets\n37,519\n74,783\nVAT recoverables\n170,564\n1,655,954\nTotal Current Assets\n35,433,952\n33,793,298\nLONG-TERM ASSETS:\nLong-term inventories, net\n10,546,648\n7,151,613\nProperty and equipment, net\n579,557\n692,116\nLand use rights and yew forest assets, net\n6,369,938\n4,558,234\nTotal Long-term Assets\n17,496,143\n12,401,963\nTotal Assets\n$\n52,930,095\n$\n46,195,261\nLIABILITIES AND SHAREHOLDERS' EQUITY\nCURRENT LIABILITIES:\nAccounts payable\n$\n460,202\n$\n2,700,148\nAccounts payable - related parties\n50,318\n638,318\nAccrued expenses and other payables\n162,619\n379,294\nNote payable\n-\n1,156,444\nTaxes payable\n5,574\n16,520\nDue to related parties\n619,999\n883,596\nShort-term borrowings\n6,099,876\n1,723,865\nTotal Current Liabilities\n7,398,588\n7,498,185\nNONCURRENT LIABILITIES:\nDeferred income\n359,646\n120,973\nTotal Noncurrent Liabilities\n359,646\n120,973\nTotal Liabilities\n7,758,234\n7,619,158\nSHAREHOLDERS' EQUITY:\nCommon Stock ($0.001 par value; 140,000,000 shares authorized; 51,875,000 shares\nissued and outstanding at December 31, 2017 and 2016)\n51,875\n51,875\nAdditional paid-in capital\n10,363,412\n9,654,024\nRetained earnings\n30,287,658\n27,074,624\nStatutory reserves\n3,762,288\n3,762,288\nAccumulated other comprehensive income (loss)\n706,628\n(1,966,708)\nTotal Shareholders' Equity\n45,171,861\n38,576,103\nTotal Liabilities and Shareholders' Equity\n$\n52,930,095\n$\n46,195,261\nYEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS)\nFor the Years Ended December 31,\n2017\n2016\nREVENUES:\nRevenues\n$\n17,634,466\n$\n22,581,267\nRevenues - related parties\n22,905,224\n28,766,815\nTotal Revenues\n40,539,690\n51,348,082\nCOST OF REVENUES:\nCost of revenues\n17,810,948\n24,688,860\nCost of revenues - related parties\n17,666,765\n23,424,644\nTotal Cost of Revenues\n35,477,713\n48,113,504\nGROSS PROFIT\n5,061,977\n3,234,578\nOPERATING EXPENSES:\nSelling\n86,633\n34,828\nGeneral and administrative\n1,650,690\n1,078,392\nTotal Operating Expenses\n1,737,323\n1,113,220\nINCOME FROM OPERATIONS\n3,324,654\n2,121,358\nOTHER INCOME (EXPENSES):\nInterest expense\n(225,023)\n(140,844)\nOther income (expense)\n(33,961)\n3,853\nExchange gains\n147,978\n40,533\nTotal Other Expenses\n(111,006)\n(96,458)\nINCOME BEFORE PROVISION FOR INCOME TAXES\n3,213,648\n2,024,900\nPROVISION FOR INCOME TAXES\n(614)\n(18,009)\nNET INCOME\n$\n3,213,034\n$\n2,006,891\nCOMPREHENSIVE INCOME (LOSS):\nNET INCOME\n$\n3,213,034\n$\n2,006,891\nOTHER COMPREHENSIVE INCOME (LOSS):\nForeign currency translation adjustment\n2,673,336\n(2,632,390)\nCOMPREHENSIVE INCOME (LOSS)\n$\n5,886,370\n$\n(625,499)\nNET INCOME PER COMMON SHARE:\nBasic\n$\n0.06\n$\n0.04\nDiluted\n$\n0.06\n$\n0.04\nWEIGHTED AVERAGE COMMON SHARES OUTSTANDING:\nBasic\n51,875,000\n51,875,000\nDiluted\n53,934,497\n51,875,000\nYEW BIO-PHARM GROUP, INC. AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF CASH FLOWS\nFor the Years Ended\nDecember 31,\n2017\n2016\nCASH FLOWS FROM OPERATING ACTIVITIES:\nNet income\n$\n3,213,034\n$\n2,006,891\nAdjustments to reconcile net income to net cash provided by (used in) operating activities:\nDepreciation\n67,790\n112,282\nAmortization of land use rights and yew forest assets\n3,678,972\n8,819,008\nStock-based compensation\n709,388\n31,466\nInventory write-down\n-\n2,499,563\nChanges in operating assets and liabilities:\nAccounts receivable\n5,349,595\n(11,345,374)\nAccounts receivable - related parties\n(13,903,716)\n(915,034)\nPrepaid and other current assets\n40,202\n(13,435)\nPrepaid expenses - related parties\n23,055\n23,440\nInventories, net\n850,356\n(4,080,175)\nVAT recoverables\n1,537,471\n(1,047,212)\nAccounts payable\n(2,325,337)\n2,807,954\nAccounts payable - related parties\n(607,503)\n626,557\nAccrued expenses and other payables\n(195,047)\n362,600\nDue to related parties\n(58,417)\n9,635\nNote payable\n(1,210,833)\n615,408\nDeferred income\n221,992\n126,392\nTaxes payable\n(11,271)\n3,065\nNET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES\n(2,620,269)\n643,031\nCASH FLOWS FROM INVESTING ACTIVITIES:\nChange in restricted cash\n-\n296,419\nPurchase of property and equipment\n-\n(61,509)\nPurchase of land use rights and yew forest assets\n(799,070)\n-\nNET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES\n(799,070)\n234,910\nCASH FLOWS FROM FINANCING ACTIVITIES:\nProceeds from short-term borrowings\n10,940,220\n1,809,189\nRepayments of short-term borrowings\n(6,844,634)\n(3,022,055)\nProceeds from related party\n-\n81\nRepayments to related parties\n(170,875)\n(49,030)\nNET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES\n3,924,711\n(1,261,815)\nEFFECT OF EXCHANGE RATE ON CASH\n75,467\n(18,743)\nNET INCREASE (DECREASE) IN CASH\n580,839\n(402,617)\nCASH - Beginning of the year\n278,991\n681,608\nCASH - End of the year\n$\n859,830\n$\n278,991\nSUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:\nCash paid for:\nInterest\n$\n189,403\n$\n145,452\nIncome taxes\n$\n18,328\n$\n24,451\nNON-CASH INVESTING AND FINANCING ACTIVITIES\nOperating expense paid by related party\n$\n38,140\n$\n88,088\nProperty and equipment paid by related party\n$\n-\n$\n82,491\nSettlement of due to related party with property and equipment\n$\n82,491\n$\n-\nReclassification of inventories to land use rights and yew forest assets\n$\n4,331,025\n$\n-\nView original content: http://www.prnewswire.com/news-releases/yew-bio-pharm-group-reports-2017-fourth-quarter-and-full-year-financial-results-300622709.html\nSOURCE Yew Bio-Pharm Group, Inc.", "external_links": ["http://www.prnewswire.com/news-releases/yew-bio-pharm-group-reports-2017-fourth-quarter-and-full-year-financial-results-300622709.html", "http://www.yewbiopharm.com/"], "published": "2018-04-03T00:10:00.000+03:00", "crawled": "2018-04-03T01:49:58.060+03:00", "highlightTitle": ""}